AR062698A1 - Aptameros marcados con 68 ga - Google Patents

Aptameros marcados con 68 ga

Info

Publication number
AR062698A1
AR062698A1 ARP070103955A ARP070103955A AR062698A1 AR 062698 A1 AR062698 A1 AR 062698A1 AR P070103955 A ARP070103955 A AR P070103955A AR P070103955 A ARP070103955 A AR P070103955A AR 062698 A1 AR062698 A1 AR 062698A1
Authority
AR
Argentina
Prior art keywords
compounds
imaging
compound according
aptameros
marked
Prior art date
Application number
ARP070103955A
Other languages
English (en)
Inventor
Maren Hecht
Ludger Dinkelborg
Lutz Lehmann
Bernhard Noll
Matthias Friebe
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR062698A1 publication Critical patent/AR062698A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compuestos basados en nucleotidos, con métodos para preparar compuestos radiomarcados, y uso de estos compuestos para el diagnostico por imágenes. Se proporcionan compuestos de acuerdo con la formula (1): A-B-L-C, donde A representa un aptámero, B está ausente o representa una estructura de union, L es un conector, y C en un quelante ionico metálico. Todos los sustituyentes se definen en detalle en la descripcion. Las realizaciones preferidas de dichos compuestos se unen a tenascina-C. Reivindicacion 13: Una composicion que comprende un compuesto de acuerdo con las reivindicaciones 1 a 12 y un vehículo o un diluyente aceptable para el uso farmacéutico. Reivindicacion 19: El uso de un compuesto de acuerdo con las reivindicaciones 1 a 12 en la fabricacion de un agente para diagnostico por imágenes, preferiblemente un agente para PET, para el diagnostico por imágenes de tumores.
ARP070103955A 2006-09-08 2007-09-07 Aptameros marcados con 68 ga AR062698A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06090165A EP1897562A1 (en) 2006-09-08 2006-09-08 Aptamers labelled with Gallium-68

Publications (1)

Publication Number Publication Date
AR062698A1 true AR062698A1 (es) 2008-11-26

Family

ID=37564205

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103955A AR062698A1 (es) 2006-09-08 2007-09-07 Aptameros marcados con 68 ga

Country Status (10)

Country Link
US (1) US20090068103A1 (es)
EP (2) EP1897562A1 (es)
JP (1) JP2010502201A (es)
AR (1) AR062698A1 (es)
CA (1) CA2662693A1 (es)
CL (1) CL2007002575A1 (es)
PE (1) PE20080660A1 (es)
TW (1) TW200812626A (es)
UY (1) UY30574A1 (es)
WO (1) WO2008028534A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI497076B (zh) 2010-06-25 2015-08-21 Univ Nat Cheng Kung 適合體及ｃ－反應蛋白檢測方法
DE102010026062A1 (de) * 2010-06-30 2012-01-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Aptamer-Komplex zur Detektion eines krankhaften Gewebes
KR20220139425A (ko) 2012-07-13 2022-10-14 웨이브 라이프 사이언시스 리미티드 키랄 제어
KR102084472B1 (ko) * 2013-10-21 2020-03-04 연세대학교 산학협력단 다양한 압타머에 적용 가능한 방사성동위원소 표지된 핵산 구조체 개발 및 표지방법
CN111856035B (zh) * 2020-07-30 2022-04-22 谱度众合(武汉)生命科技有限公司 一种tnc蛋白检测试剂的应用及试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands

Also Published As

Publication number Publication date
JP2010502201A (ja) 2010-01-28
EP1897562A1 (en) 2008-03-12
UY30574A1 (es) 2008-05-02
PE20080660A1 (es) 2008-08-01
TW200812626A (en) 2008-03-16
EP2063917A1 (en) 2009-06-03
WO2008028534A1 (en) 2008-03-13
US20090068103A1 (en) 2009-03-12
CL2007002575A1 (es) 2008-05-23
CA2662693A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
NI200500164A (es) Nueva difenilazetidinona con caracteristicas fisiologicas mejoradas, correspondiente metodo de produccion, medicamentos que contienen dicho compuesto y su uso.
CL2004000416A1 (es) Compuestos heterociclicos nitrogenados; composicion farmaceutica; y uso del compuesto para tratar o prevenir una condicion mediada por p38, que consiste en una enfermedad inflamatoria, autoinmune, virosica o neurodegenerativa.
NO20071880L (no) Diagnostic Compounds
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
AR050254A1 (es) Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas
CL2007001759A1 (es) Compuesto metformina r-(+) lipoato; mezcla que comprende metformina y acido r-(+) lipoico; composicion farmaceutica que comprende el compuesto; metodo para preparar el compuesto; kit; y uso para tratar la diabetes.
BRPI0613429A2 (pt) inibidores de histona desacetilase
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA200701362A1 (ru) Агонисты glp-1, композиции, способы и применения
BRPI0720105A2 (pt) Conjugados de aminoácido não padrões de anfetamina e processos para fabricação e uso dos mesmos
CY1115078T1 (el) Παραγωγα πυραζολοαμινοπυριδινης χρησιμα ως αναστολεις της κινασης
CY1111579T1 (el) Νεα συνδυασμενη χρηση μιας ενωσης σουλφοναμιδης (sulfonamide) στην θεραπεια του καρκινου
AR062698A1 (es) Aptameros marcados con 68 ga
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
CL2008003057A1 (es) Combinacion farmaceutica que comprende un derivado de purina y un corticoide, agonista de beta-2 adrenoceptor, agente antimuscarinico, entre otros; composicion farmaceutica; y su uso para tratar enfermedades inflamatorias u obstructivas de las vias respiratorias.
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
NO20032788L (no) Modafinil-forbindelse og cyklodekstrinblandinger
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
DE60312136D1 (de) Radiofluorierungsverfahren
PE20080949A1 (es) Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que los contienen
PA8747601A1 (es) Marcaciòn con fluor radioactivo
AR073871A1 (es) Intermediario de fulvestran
RU2009138470A (ru) Композиция для наружного применения на коже

Legal Events

Date Code Title Description
FB Suspension of granting procedure